Cargando…

TP0586532, a Novel Non-Hydroxamate LpxC Inhibitor: Potentiating Effect on In Vitro Activity of Meropenem against Carbapenem-Resistant Enterobacteriaceae

Carbapenem-resistant Enterobacteriaceae (CRE) are an urgent threat to public health requiring the development of novel therapies. TP0586532 is a novel non-hydroxamate LpxC inhibitor that inhibits the synthesis of lipopolysaccharides, which are components of the outer membranes of Gram-negative bacte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshida, Ippei, Takata, Iichiro, Fujita, Kiyoko, Takashima, Hajime, Sugiyama, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9241751/ https://www.ncbi.nlm.nih.gov/pubmed/35647694 http://dx.doi.org/10.1128/spectrum.00828-22

Ejemplares similares

TP0586532, a non-hydroxamate LpxC inhibitor, reduces LPS release and IL-6 production both in vitro and in vivo
por: Fujita, Kiyoko, et al.
Publicado: (2022)

The nucleotide-binding site of Aquifex aeolicus LpxC
por: Buetow, Lori, et al.
Publicado: (2006)

Interplay of Klebsiella pneumoniae fabZ and lpxC Mutations Leads to LpxC Inhibitor-Dependent Growth Resulting from Loss of Membrane Homeostasis
por: Mostafavi, Mina, et al.
Publicado: (2018)

Regulated Expression of lpxC Allows for Reduction of Endotoxicity in Bordetella pertussis
por: Pérez-Ortega, Jesús, et al.
Publicado: (2022)

Machine learning approaches to study the structure-activity relationships of LpxC inhibitors
por: Yu, Tianshi, et al.
Publicado: (2023)

Chlamydia spp. development is differentially altered by treatment with the LpxC inhibitor LPC-011
por: Cram, Erik D., et al.
Publicado: (2017)

An Essential Membrane Protein Modulates the Proteolysis of LpxC to Control Lipopolysaccharide Synthesis in Escherichia coli
por: Fivenson, Elayne M., et al.
Publicado: (2020)

A New Factor LapD Is Required for the Regulation of LpxC Amounts and Lipopolysaccharide Trafficking
por: Wieczorek, Alicja, et al.
Publicado: (2022)

Inhibition of LpxC Protects Mice from Resistant Acinetobacter baumannii by Modulating Inflammation and Enhancing Phagocytosis
por: Lin, Lin, et al.
Publicado: (2012)

3D-QSAR, Molecular Docking and Molecular Dynamics Simulation of Pseudomonas aeruginosa LpxC Inhibitors
por: Zuo, Ke, et al.
Publicado: (2017)

Inhibition of LpxC Increases the Activity of Iron Chelators and Gallium Nitrate in Multidrug-Resistant Acinetobacter baumannii
por: Vinuesa, Víctor, et al.
Publicado: (2021)

Intricate Crosstalk Between Lipopolysaccharide, Phospholipid and Fatty Acid Metabolism in Escherichia coli Modulates Proteolysis of LpxC
por: Thomanek, Nikolas, et al.
Publicado: (2019)

Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC
por: Lemaître, Nadine, et al.
Publicado: (2017)

Application of LpxC enzyme inhibitor to inhibit some fast-growing bacteria in human gut bacterial culturomics
por: Hou, Fengyi, et al.
Publicado: (2019)

LpxC Inhibitors as New Antibacterial Agents and Tools for Studying Regulation of Lipid A Biosynthesis in Gram-Negative Pathogens
por: Tomaras, Andrew P., et al.
Publicado: (2014)

Suppressors of lapC Mutation Identify New Regulators of LpxC, Which Mediates the First Committed Step in Lipopolysaccharide Biosynthesis
por: Maniyeri, Akshay, et al.
Publicado: (2023)

Application of mouse model for evaluation of recombinant LpxC and GmhA as novel antigenic vaccine candidates of Glaesserella parasuis serotype 13
por: JIA, Yong C., et al.
Publicado: (2021)

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae
por: Petty, Lindsay A, et al.
Publicado: (2018)

lpxC and yafS are the Most Suitable Internal Controls to Normalize Real Time RT-qPCR Expression in the Phytopathogenic Bacteria Dickeya dadantii
por: Hommais, Florence, et al.
Publicado: (2011)

Regulation of the First Committed Step in Lipopolysaccharide Biosynthesis Catalyzed by LpxC Requires the Essential Protein LapC (YejM) and HslVU Protease
por: Biernacka, Daria, et al.
Publicado: (2020)

Bactericidal efficacy of meropenem in combination with cefmetazole against IMP-producing carbapenem-resistant Enterobacteriaceae
por: Abe, Ryuichiro, et al.
Publicado: (2019)

1618. Meropenem-vaborbactam vs standard of care for multidrug resistant carbapenem-resistant Enterobacteriaceae
por: Misikir, Helina, et al.
Publicado: (2020)

Carbapenem-Resistant Enterobacteriaceae Bloodstream Infection Treated Successfully With High-Dose Meropenem in a Preterm Neonate
por: Wu, Yue-E, et al.
Publicado: (2020)

2247. Real-world Experience with Meropenem–Vaborbactam (M/V) for Treatment of Carbapenem-Resistant Enterobacteriaceae (CRE) Infections
por: Shields, Ryan K, et al.
Publicado: (2019)

1378. Evaluation of the In vitro Activity of Meropenem-Vaborbactam Against Carbapenem-Resistant Enterobacteriaceae, Including Isolates Resistant to Ceftazidime–Avibactam
por: Wilson, William R, et al.
Publicado: (2018)

Curcumin-meropenem synergy in carbapenem resistant Klebsiella pneumoniae curcumin-meropenem synergy
por: Gülen, Dumrul, et al.
Publicado: (2021)

2266. Management of Ertapenem-Resistant, Meropenem-Susceptible Enterobacteriaceae
por: Srinivas, Pavithra, et al.
Publicado: (2019)

662. Recurrence of Infection and Emergence of Drug Resistance After Treatment with Meropenem/Vaborbactam Compared with Ceftazidime/Avibactam in Carbapenem-Resistant Enterobacteriaceae Infections
por: Ackley, Renee, et al.
Publicado: (2019)

Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan
por: Wang, Jann-Tay, et al.
Publicado: (2015)

Resistance Pattern of Carbapenem on Enterobacteriaceae
por: Pokharel, Khilasa, et al.
Publicado: (2018)

Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
por: Wunderink, Richard G., et al.
Publicado: (2018)

2416. Risk Factors and Outcomes of Bacteremia Caused by Carbapenem-Resistant Enterobacteriaceae Compared With Carbapenem Susceptible Enterobacteriaceae
por: Mahmood, Syed Faisal
Publicado: (2018)

Identification of lptA, lpxE, and lpxO, Three Genes Involved in the Remodeling of Brucella Cell Envelope
por: Conde-Álvarez, Raquel, et al.
Publicado: (2018)

Vital Signs: Carbapenem-Resistant Enterobacteriaceae
por: Jacob, Jesse T., et al.
Publicado: (2013)

Clinical Outcomes and Safety of Meropenem–Colistin versus Meropenem–Tigecycline in Patients with Carbapenem-Resistant Acinetobacter baumannii Pneumonia
por: Park, Jae-Min, et al.
Publicado: (2021)

257 In Vitro Activity of Meropenem/RPX7009, a Carbapenem/β-lactamase Inhibitor Combination Tested Against Contemporary Populations of Enterobacteriaceae and KPC-producing Strains
por: Castanheira, Mariana, et al.
Publicado: (2014)

In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae
por: Hackel, Meredith A., et al.
Publicado: (2017)

Synergistic Activity of Equol and Meropenem against Carbapenem-Resistant Escherichia coli
por: Kim, Hye-Rim, et al.
Publicado: (2021)

The Place of Meropenem–Vaborbactam in the Management of Carbapenem-Resistant Gram-Negative Infections
por: Chopra, Teena
Publicado: (2021)

Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections
por: Falagas, Matthew E., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kd1hcmnncsglhl339u9c1b0mim